bluebird bio (BLUE)
(Delayed Data from NSDQ)
$0.49 USD
0.00 (-0.61%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $0.49 0.00 (-0.41%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for bluebird bio, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 180 | 300 | 1,151 | 1,106 |
Receivables | NA | 11 | 11 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 26 | 64 | 46 |
Total Current Assets | NA | 199 | 337 | 1,216 | 1,152 |
Net Property & Equipment | NA | 9 | 10 | 163 | 151 |
Investments & Advances | NA | 1 | 97 | 123 | 132 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 11 | 6 | 23 | 27 |
Deposits & Other Assets | NA | 52 | 53 | 73 | 79 |
Total Assets | NA | 555 | 594 | 1,781 | 1,727 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 25 | 26 | 22 | 43 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 52 | 104 | 145 | 142 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 12 | 19 |
Total Current Liabilities | NA | 128 | 153 | 204 | 224 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 26 | 10 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 29 | 38 |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 359 | 220 | 426 | 442 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 1 | 1 | 1 | 1 |
Capital Surplus | NA | 4,186 | 4,096 | 4,260 | 3,568 |
Retained Earnings | NA | -3,987 | -3,720 | -2,901 | -2,282 |
Other Equity | NA | -4 | -3 | -6 | -2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 196 | 374 | 1,355 | 1,285 |
Total Liabilities & Shareholder's Equity | NA | 555 | 594 | 1,781 | 1,727 |
Total Common Equity | 0 | 196 | 374 | 1,355 | 1,285 |
Shares Outstanding | 109.34 | 82.92 | 70.10 | 66.30 | 55.30 |
Book Value Per Share | 0.00 | 2.37 | 5.34 | 20.44 | 23.24 |
Fiscal Year End for bluebird bio, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | -99,999 | -99,999 | 174 | 245 |
Receivables | NA | NA | NA | 23 | 0 |
Notes Receivable | NA | NA | NA | 0 | 0 |
Inventories | NA | NA | NA | 21 | 14 |
Other Current Assets | NA | NA | NA | 29 | 29 |
Total Current Assets | NA | NA | NA | 247 | 288 |
Net Property & Equipment | NA | NA | NA | 10 | 10 |
Investments & Advances | NA | NA | NA | 0 | 0 |
Other Non-Current Assets | NA | NA | NA | 0 | 0 |
Deferred Charges | NA | NA | NA | 0 | 0 |
Intangibles | NA | NA | NA | 11 | 11 |
Deposits & Other Assets | NA | NA | NA | 51 | 51 |
Total Assets | NA | NA | NA | 614 | 663 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | NA | NA | 0 | 0 |
Accounts Payable | NA | NA | NA | 20 | 11 |
Current Portion Long-Term Debt | NA | NA | NA | 0 | 0 |
Current Portion Capital Leases | NA | NA | NA | 0 | 0 |
Accrued Expenses | NA | NA | NA | 58 | 57 |
Income Taxes Payable | NA | NA | NA | 0 | 0 |
Other Current Liabilities | NA | NA | NA | 10 | 0 |
Total Current Liabilities | NA | NA | NA | 159 | 135 |
Mortgages | NA | NA | NA | 0 | 0 |
Deferred Taxes/Income | NA | NA | NA | 0 | 0 |
Convertible Debt | NA | NA | NA | 0 | 0 |
Long-Term Debt | NA | NA | NA | 0 | 0 |
Non-Current Capital Leases | NA | NA | NA | 0 | 0 |
Other Non-Current Liabilities | NA | NA | 0 | 0 | |
Minority Interest (Liabilities) | NA | NA | NA | 0 | 0 |
Total Liabilities | NA | NA | NA | 391 | 374 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | NA | NA | 0 | 0 |
Common Stock (Par) | NA | NA | NA | 1 | 1 |
Capital Surplus | NA | NA | NA | 4,334 | 4,328 |
Retained Earnings | NA | NA | NA | -4,110 | -4,038 |
Other Equity | NA | NA | NA | -2 | -2 |
Treasury Stock | NA | NA | NA | 0 | 0 |
Total Shareholder's Equity | NA | NA | NA | 223 | 289 |
Total Liabilities & Shareholder's Equity | NA | NA | NA | 614 | 663 |
Total Common Equity | 0 | 0 | 0 | 223 | 289 |
Shares Outstanding | 109.34 | 109.34 | 109.30 | 106.90 | 106.40 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 2.08 | 2.72 |